Which antipsychotic medications are associated with flashing‑light visual disturbances (photopsia)?

Antipsychotics and Photopsia (Flashing Lights)

Paroxetine (an SSRI, not an antipsychotic) shows the strongest association with photopsia (flashing lights), while risperidone is the only antipsychotic documented to cause visual illusions resembling flashing lights or hallucinogen-like visual disturbances. 1, 2

Antipsychotic-Related Visual Phenomena

Risperidone: Primary Antipsychotic Concern

• Risperidone has been documented to cause posthallucinogen-like visual illusions (palinopsia) that can include flashing lights or other visual disturbances, even in patients without any history of hallucinogen exposure. 1

• These visual phenomena typically occur after dose increases and generally remit within 48 hours. 1

• The mechanism is thought to involve serotonin 5HT2a receptor blockade rather than increased 5HT2c stimulation. 1

• Patients with heightened sensitivity to medication side effects appear to be at greater risk for these visual disturbances. 1

Other Antipsychotic Ocular Effects (Not Flashing Lights)

While other antipsychotics cause various ocular problems, they are not specifically associated with photopsia or flashing lights:

• Quetiapine: Associated with cataract development in animal studies; FDA recommends baseline and 6-month eye examinations, but not linked to flashing lights. 3, 4

• Thioridazine and chlorpromazine: Cause lenticular stippling, corneal deposits, and retinopathy at high doses, but these manifest as pigmentary changes rather than flashing lights. 4, 5

• High-potency antipsychotics (haloperidol): Primarily cause oculogyric crisis (dystonic eye movements) rather than photopsia. 3

Important Clinical Distinction

Photopsia is more strongly associated with SSRIs than antipsychotics, particularly paroxetine, which shows the highest risk among psychiatric medications. 2

SSRI-Related Photopsia

• A real-world analysis of FDA adverse event data revealed paroxetine has the strongest association with photopsia among all SSRIs. 2

• Other SSRIs (escitalopram, citalopram, fluoxetine) are more commonly associated with vision blurred, visual impairment, and mydriasis rather than flashing lights. 2

• Most SSRI-related eye disorders occur within the first 30 days of treatment. 2

Clinical Management Algorithm

If a patient reports flashing lights while on psychiatric medication:

1. Identify the medication: Determine if the patient is taking risperidone, paroxetine, or other SSRIs. 1, 2

2. Assess timing: Visual phenomena with risperidone typically occur within 48 hours of dose increases. 1

3. Rule out serious causes: Ensure symptoms are not due to retinal detachment, posterior vitreous detachment, or other ophthalmologic emergencies requiring immediate evaluation. 5, 6

4. For risperidone-related photopsia: Consider dose reduction or switching to an alternative antipsychotic with different receptor profile (e.g., aripiprazole, which has negligible cardiac and visual effects). 4, 1

5. For SSRI-related photopsia: Consider switching from paroxetine to an SSRI with lower photopsia risk. 2

Monitoring Recommendations

• Baseline eye examination is recommended before initiating quetiapine (due to cataract risk), but routine ophthalmologic screening for photopsia is not standard for other antipsychotics. 3, 4

• Patients should be educated to report visual disturbances immediately, as early recognition allows for prompt intervention. 3, 1